Application study of stool-based methylated SDC2 test in the screening of colorectal neoplasms for physical examination population.
10.3760/cma.j.cn112150-20220314-00233
- Author:
Li WANG
1
;
Zhan Mei HUANG
2
;
Yan Ying JIANG
1
;
Min ZHU
1
;
Nian ZHANG
1
;
Feng Bao XIONG
3
;
Hong Zhi ZOU
4
;
Xiao Hui XU
1
Author Information
1. Gastroenterology Department, The First People's Hospital of Xiushui County, Jiujiang 332400, China.
2. Health Management Center, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
3. Gastroenterology Department, The First Hospital of Nanchang, Nanchang 330008, China.
4. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China.
- Publication Type:Journal Article
- MeSH:
Male;
Female;
Humans;
Middle Aged;
Sensitivity and Specificity;
Prospective Studies;
Early Detection of Cancer/methods*;
Colorectal Neoplasms/diagnosis*;
Mass Screening/methods*;
Feces;
DNA Methylation;
Colonoscopy;
Physical Examination;
Syndecan-2/genetics*
- From:
Chinese Journal of Preventive Medicine
2022;56(12):1767-1773
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the value of stool-based methylated SDC2 test in physical examination population for the screening of colorectal neoplasms. Methods: Using the prospective cohort study method, from December 2020 to November 2021, 2 107 participants from the First People's Hospital of Xiushui County, Jiangxi Province were enrolled, consisted of 1 012 males and 1 094 females, aged 20-90 years with the median age of 49 years old. Fresh stool samples were collected and SDC2 DNA methylation tests were carried out as the primary screening method. The participants with positive results were recommended to undergo colonoscopy, and those who were negative were followed up by telephone. The positive rate of screening, the compliance of colonoscopy, and the detection of colorectal lesions were analyzed by chi-square test. Combined the follow-up results of negative subjects, the value of SDC2 DNA methylation test for the screening of colorectal neoplasms was evaluated. Results: Among the 2 107 participants, 2 106 completed the SDC2 methylation test. 113 participants (5.4%) were positive. The positive rate of primary screening increased with age significantly (χ2=32.135, P<0.001). Out of 113 cases, 72 (63.7%) underwent colonoscopy examinations. Finally, 3 (4.2%) cases of colorectal cancer, 12 (16.7%) cases of advanced adenoma, 31 (43.1%) cases of non-advanced adenoma, and 16 (22.2%) cases of non-adenomatous polyp were detected. The positive predictive value (PPV) of stool-based SDC2 DNA methylation test for intestinal lesions and colorectal neoplasms were 86.1% and 63.9%, respectively. Among the 1 374 follow-up participants, the negative predictive value (NPV) of this test for intestinal lesions and colorectal neoplasms were 97.7% and 99.4%, respectively. Conclusion: Primary stool-based SDC2 DNA methylation test and subsequent colonoscopy examination can effectively find colorectal neoplasms. This strategy may be a potential tool for the screening of colorectal neoplasms in general risk population.
